Ruibotec Biomedical Technology

Explore the latest insights on Ruibotec Biomedical Technology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Ruibotec Biomedical Technology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer
CompanyDrug

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals announced that the first subject has been enrolled and dosed in the Phase II clinical study of DAT‑2645, the company's independently developed Class 1 innovative drug, at the…

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now